Amphastar Pharmaceuticals (AMPH) Non-Current Assets (2013 - 2026)
Amphastar Pharmaceuticals (AMPH) posted quarterly Non-Current Assets of $1.0 billion for Q1 2026, down 2.3% year-over-year from $1.0 billion in Q1 2025, and up 2.13% quarter-over-quarter from $993.3 million in Q4 2025.
Amphastar Pharmaceuticals (AMPH) Non-Current Assets (2013 - 2026) Analysis & Trends
Amphastar Pharmaceuticals' Non-Current Assets history runs 14 years deep, the most recent figure standing at $1.0 billion for Q1 2026.
- In Q1 2026, Non-Current Assets fell 2.3% year-over-year to $1.0 billion; the TTM figure through Mar 2026 stood at $4.1 billion (down 0.51% YoY), while the FY2025 annual figure was $993.3 million, down 4.8% from the prior year.
- Non-Current Assets for Q1 2026 stood at $1.0 billion, up from $993.3 million in the prior quarter.
- The five-year high for Non-Current Assets was $1.0 billion in Q4 2024, with the low at $342.5 million in Q3 2022.
- The 5-year median for Non-Current Assets is $1.0 billion (2023), against an average of $821.6 million.
- The sharpest annual moves came in 2023 and 2025: Non-Current Assets jumped 192.47% in 2023, then dropped 4.8% in 2025.
- Amphastar Pharmaceuticals' Non-Current Assets stood at $363.7 million in 2022, then jumped by 181.39% to $1.0 billion in 2023, then advanced by 1.96% to $1.0 billion in 2024, then decreased by 4.8% to $993.3 million in 2025, then climbed by 2.13% to $1.0 billion in 2026.
- Business Quant data shows AMPH's Non-Current Assets at $1.0 billion in Q1 2026, $993.3 million in Q4 2025, and $1.0 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 2.96 Bn |
| 10 | Amphastar Pharmaceuticals | 943.15 Mn | 653.02 Mn | 93.47 Mn | 1.11 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.11 Bn |
| Mar 31, 2026 | 1.01 Bn |
| Dec 31, 2025 | 993.28 Mn |
| Sep 30, 2025 | 1.03 Bn |
| Jun 30, 2025 | 1.03 Bn |
| Mar 31, 2025 | 1.04 Bn |
| Dec 31, 2024 | 1.04 Bn |
| Sep 30, 2024 | 999.23 Mn |
| Jun 30, 2024 | 1.01 Bn |
| Mar 31, 2024 | 1.02 Bn |
| Dec 31, 2023 | 1.02 Bn |
| Sep 30, 2023 | 1.00 Bn |
| Jun 30, 2023 | 993.71 Mn |
| Mar 31, 2023 | 365.99 Mn |
| Dec 31, 2022 | 363.67 Mn |
| Sep 30, 2022 | 342.47 Mn |
| Jun 30, 2022 | 346.57 Mn |
| Mar 31, 2022 | 351.82 Mn |
| Dec 31, 2021 | 353.41 Mn |
| Sep 30, 2021 | 348.01 Mn |